CRIS - Curis Inc Stock Price, Fair Value and News

$3.17-0.08 (-2.46%)

Delayed as of 30 Dec 2024, 11:19 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CRIS Price Action

Last 7 days

5.5%

Last 30 days

-27.0%

Last 90 days

-39.6%

Trailing 12 Months

-76.6%

CRIS RSI Chart

CRIS Valuation

Market Cap

27.5M

Price/Earnings (Trailing)

-0.61

Price/Sales (Trailing)

2.68

Price/Free Cashflow

-0.68

CRIS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CRIS Fundamentals

CRIS Revenue

Revenue (TTM)

10.3M

Rev. Growth (Yr)

3.46%

Rev. Growth (Qtr)

15.12%

CRIS Earnings

Earnings (TTM)

-45.5M

Earnings Growth (Yr)

17.15%

Earnings Growth (Qtr)

14.5%

CRIS Profitability

Return on Equity

520.7%

Return on Assets

-107.09%

Free Cashflow Yield

-147.13%

CRIS Investor Care

Shares Dilution (1Y)

43.92%

Diluted EPS (TTM)

-7.76

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.8M	10.2M	10.3M	0
2023	10.4M	10.2M	10.2M	10.0M
2022	10.5M	10.6M	10.4M	10.2M
2021	10.3M	10.2M	10.5M	10.6M
2020	10.9M	11.2M	11.1M	10.8M
2019	9.7M	9.5M	9.5M	10.0M
2018	10.2M	10.5M	10.9M	10.4M
2017	7.9M	8.3M	9.0M	9.9M
2016	7.9M	7.5M	7.3M	7.5M
2015	10.2M	7.5M	7.8M	7.9M
2014	15.4M	14.8M	9.4M	9.8M
2013	7.5M	8.5M	15.2M	15.0M
2012	19.6M	24.5M	29.4M	17.0M
2011	15.7M	15.4M	15.1M	14.8M
2010	0	11.1M	13.5M	16.0M
2009	0	0	0	8.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Curis Inc

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CEO	Mr. James E. Dentzer
WEBSITE	curis.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	51

Curis Inc Frequently Asked Questions

What is the ticker symbol for Curis Inc? What does CRIS stand for in stocks?

CRIS is the stock ticker symbol of Curis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Curis Inc (CRIS)?

As of Fri Dec 27 2024, market cap of Curis Inc is 27.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRIS stock?

You can check CRIS's fair value in chart for subscribers.

Is Curis Inc a good stock to buy?

The fair value guage provides a quick view whether CRIS is over valued or under valued. Whether Curis Inc is cheap or expensive depends on the assumptions which impact Curis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRIS.

What is Curis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 27 2024, CRIS's PE ratio (Price to Earnings) is -0.61 and Price to Sales (PS) ratio is 2.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRIS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Curis Inc's stock?

In the past 10 years, Curis Inc has provided -0.074 (multiply by 100 for percentage) rate of return.